undamentalytics Newsletter
Sign in

Sonoma Pharmaceuticals, Inc. income statement

In fiscal 2026, Sonoma Pharmaceuticals, Inc. reported revenue of $19.5m, up 36.7% on the year before, operating income of −$2.5m (a -12.6% margin) and net income of −$3.2m, or −$1.89 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Mar 20112012Mar 20122013Mar 20132014Mar 20142015Mar 20152016Mar 20162017Mar 20172018Mar 20182019Mar 20192020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Revenue101315141491317191819131313142022
Cost of revenue4455777910101299891213
Gross profit691187367987445579
Research and development22232222211002222
Selling, general and administrative1213121212161720191491098788
Operating income−8−6−3−6−7−15−13−14−11−7−3−6−5−5−4−2−1
Interest expense01110000000——————
Net interest income——————————0−00————
Income before tax—————−15−13−14−11−4−4−5−5−5−3−3−3
Income tax—−10000−40001−0−0−01−0−0
Net income−8−7−54−8−109−14−12−3−4−5−5−5−3−3−2
Diluted EPS−$270.00−$1683.00−$1170.00$486.00−$765.00−$556.20$2.20−$569.80−$255.40−$2.24−$39.40−$38.40−$30.40−$10.63−$2.79−$1.89−$1.01
Diluted shares (average)29m—6m8m11m18m————————1m2m2m
EBITDA−7−6−3−6−6−14−13−14−11−7−3−6−4−5−4−2−1

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BDMD vs SNOASNOA vs VVOSNEPH vs SNOASNOA vs ZJYL

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Sonoma Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sonoma Pharmaceuticals, Inc.